Atria Wealth Solutions Inc. Sells 518 Shares of Bristol-Myers Squibb (NYSE:BMY)

Atria Wealth Solutions Inc. lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 0.3% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 193,629 shares of the biopharmaceutical company’s stock after selling 518 shares during the period. Atria Wealth Solutions Inc.’s holdings in Bristol-Myers Squibb were worth $13,932,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. grew its position in Bristol-Myers Squibb by 1.7% in the first quarter. BlackRock Inc. now owns 175,584,734 shares of the biopharmaceutical company’s stock valued at $12,169,778,000 after acquiring an additional 2,856,746 shares during the period. Ameriprise Financial Inc. increased its position in shares of Bristol-Myers Squibb by 10.3% during the 1st quarter. Ameriprise Financial Inc. now owns 26,084,266 shares of the biopharmaceutical company’s stock worth $1,807,487,000 after purchasing an additional 2,439,814 shares in the last quarter. Norges Bank acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $1,873,696,000. Moneta Group Investment Advisors LLC grew its stake in Bristol-Myers Squibb by 114,228.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock worth $1,544,751,000 after buying an additional 21,451,006 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of Bristol-Myers Squibb by 7.0% during the first quarter. Deutsche Bank AG now owns 19,381,102 shares of the biopharmaceutical company’s stock worth $1,343,304,000 after buying an additional 1,263,969 shares in the last quarter. Institutional investors and hedge funds own 74.98% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the topic of a number of research analyst reports. Atlantic Securities decreased their price target on Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, July 28th. Daiwa Capital Markets initiated coverage on Bristol-Myers Squibb in a research report on Wednesday, June 28th. They issued an “outperform” rating and a $70.00 price objective on the stock. Cantor Fitzgerald cut their price target on Bristol-Myers Squibb from $88.00 to $85.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 19th. Bank of America lowered their price target on shares of Bristol-Myers Squibb from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Friday, July 28th. Finally, HSBC initiated coverage on Bristol-Myers Squibb in a research note on Friday, July 14th. They issued a “reduce” rating and a $56.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $71.14.

Bristol-Myers Squibb Stock Down 1.0 %

Shares of Bristol-Myers Squibb stock opened at $59.66 on Thursday. The firm has a market cap of $124.64 billion, a PE ratio of 15.87, a P/E/G ratio of 1.58 and a beta of 0.42. The business’s 50 day simple moving average is $61.88 and its 200 day simple moving average is $65.33. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.28 and a current ratio of 1.39. Bristol-Myers Squibb has a 52-week low of $59.45 and a 52-week high of $81.43.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). Bristol-Myers Squibb had a net margin of 17.62% and a return on equity of 50.51%. The business had revenue of $11.23 billion during the quarter, compared to analyst estimates of $11.81 billion. During the same quarter last year, the business earned $1.93 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb will post 7.49 earnings per share for the current fiscal year.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Ann Powell sold 17,986 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the sale, the executive vice president now owns 27,868 shares in the company, valued at $1,706,915. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the transaction, the executive vice president now directly owns 27,868 shares in the company, valued at $1,706,915. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Robert M. Plenge sold 732 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total value of $44,754.48. Following the transaction, the executive vice president now owns 6,584 shares of the company’s stock, valued at approximately $402,545.76. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.